US 12,442,825 B2
Prescription of remote patient management based on biomarkers
Tobias Stubbe, Hennigsdorf (DE); Jan Wiemer, Hennigsdorf (DE); Jan Kunde, Hennigsdorf (DE); Stefan Gehrig, Hennigsdorf (DE); and Friedrich Köhler, Berlin (DE)
Assigned to B.R.A.H.M.S GmbH, Hennigsdorf (DE)
Appl. No. 17/599,157
Filed by B.R.A.H.M.S GmbH, Hennigsdorf (DE)
PCT Filed Mar. 27, 2020, PCT No. PCT/EP2020/058700
§ 371(c)(1), (2) Date Sep. 28, 2021,
PCT Pub. No. WO2020/201078, PCT Pub. Date Oct. 8, 2020.
Claims priority of application No. 19166382 (EP), filed on Mar. 29, 2019; application No. 19166425 (EP), filed on Mar. 29, 2019; and application No. 19175720 (EP), filed on May 21, 2019.
Prior Publication US 2022/0260589 A1, Aug. 18, 2022
Int. Cl. G01N 33/68 (2006.01); G01N 33/70 (2006.01); G01N 33/74 (2006.01)
CPC G01N 33/6893 (2013.01) [G01N 33/70 (2013.01); G01N 33/74 (2013.01); G01N 2333/58 (2013.01); G01N 2800/325 (2013.01); G01N 2800/52 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method for administering a remote patient management for a patient diagnosed with a cardiovascular disease, the method comprising:
providing at least one sample of said patient,
determining a level of at least one biomarker selected from the group consisting of pro adrenomedullin (proADM), pro brain natriuretic peptide (proBNP) and/or pro atrial natriuretic peptide (proANP) or fragment(s) thereof to be a high benefit level in said at least one sample, wherein the high benefit level is above one or more reference values, and
administering the remote patient management for said patient.